Obtention of new disease specific biomarkers are a must to achieve success in nanodiagnostics, as well as in targeted delivery. There is an increasingly growing request of them to confront several diseases and clinical conditions (i.e. markers for treatment response, immune system activation or disease stratification). These biomarkers are also essential for developing targeting strategies needed to biofunctionalyze nanoparticles against them to deliver traceable particles (imaging) and therapeutic drugs (drug delivery).